RATIONALE AND OBJECTIVES: Fibrin deposition has been indicated within the stroma of a majority of solid tumors. Here we assess the feasibility of using the established fibrin-specific probe EP-2104R for noninvasive imaging of fibrin in the context of breast cancer. METHODS: EP-2104R, untargeted gadopentetate dimeglumine (Gd-DTPA), and a newly synthesized nonfibrin binding control linear peptide (CLP) were compared using steady-state and dynamic contrast-enhanced magnetic resonance imaging in a breast cancer xenograft mouse model at 9.4 T. RESULTS: EP-2104R transiently enhanced both tumor core and tumor periphery, but only the enhancement in the tumor periphery persisted even 90 minutes after EP-2104R administration. However, untargeted Gd-DTPA and CLP are not retained in the tumor periphery. The half-life of EP-2104R in the tumor periphery (103 ± 18 minutes) is significantly longer (P < 0.05) than that of either Gd-DTPA (29.6 ± 2.4 minutes) or CLP (42.4 ± 1.5 minutes), but the rate of clearance is similar for all the 3 probes from the tumor core. The presence of high concentrations of fibrin in the tumor periphery was corroborated using immunohistochemistry with a fibrin-specific antibody. CONCLUSIONS: The persistent enhancement observed in the tumor periphery with EP-2104R is likely a result of its fibrin-specific binding rather than its size and demonstrates the feasibility of EP-2104R for molecular imaging of fibrin in tumor stroma.
RATIONALE AND OBJECTIVES: Fibrin deposition has been indicated within the stroma of a majority of solid tumors. Here we assess the feasibility of using the established fibrin-specific probe EP-2104R for noninvasive imaging of fibrin in the context of breast cancer. METHODS:EP-2104R, untargeted gadopentetate dimeglumine (Gd-DTPA), and a newly synthesized nonfibrin binding control linear peptide (CLP) were compared using steady-state and dynamic contrast-enhanced magnetic resonance imaging in a breast cancer xenograft mouse model at 9.4 T. RESULTS:EP-2104R transiently enhanced both tumor core and tumor periphery, but only the enhancement in the tumor periphery persisted even 90 minutes after EP-2104R administration. However, untargeted Gd-DTPA and CLP are not retained in the tumor periphery. The half-life of EP-2104R in the tumor periphery (103 ± 18 minutes) is significantly longer (P < 0.05) than that of either Gd-DTPA (29.6 ± 2.4 minutes) or CLP (42.4 ± 1.5 minutes), but the rate of clearance is similar for all the 3 probes from the tumor core. The presence of high concentrations of fibrin in the tumor periphery was corroborated using immunohistochemistry with a fibrin-specific antibody. CONCLUSIONS: The persistent enhancement observed in the tumor periphery with EP-2104R is likely a result of its fibrin-specific binding rather than its size and demonstrates the feasibility of EP-2104R for molecular imaging of fibrin in tumor stroma.
Authors: Patrick M Winter; Kejia Cai; Junjie Chen; Christopher R Adair; Garry E Kiefer; Phillip S Athey; Patrick J Gaffney; Carolyn E Buff; J David Robertson; Shelton D Caruthers; Samuel A Wickline; Gregory M Lanza Journal: Magn Reson Med Date: 2006-12 Impact factor: 4.668
Authors: Elmar Spuentrup; Marcus Katoh; Andrea J Wiethoff; Edward C Parsons; Rene M Botnar; Andreas H Mahnken; Rolf W Günther; Arno Buecker Journal: Am J Respir Crit Care Med Date: 2005-06-03 Impact factor: 21.405
Authors: Dipanjan Pan; Shelton D Caruthers; Angana Senpan; Ceren Yalaz; Allen J Stacy; Grace Hu; Jon N Marsh; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza Journal: J Am Chem Soc Date: 2011-05-26 Impact factor: 15.419
Authors: Patrick M Winter; Shelton D Caruthers; Xin Yu; Sheng-Kwei Song; Junjie Chen; Brad Miller; Jeff W M Bulte; J David Robertson; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza Journal: Magn Reson Med Date: 2003-08 Impact factor: 4.668
Authors: Elmar Spuentrup; Rene M Botnar; Andrea J Wiethoff; Tareq Ibrahim; Sebastian Kelle; Marcus Katoh; Murat Ozgun; Eike Nagel; Josef Vymazal; Phil B Graham; Rolf W Günther; David Maintz Journal: Eur Radiol Date: 2008-04-19 Impact factor: 5.315
Authors: Karl Turetschek; Anda Preda; Viktor Novikov; Robert C Brasch; Hanns J Weinmann; Patrick Wunderbaldinger; Timothy P L Roberts Journal: J Magn Reson Imaging Date: 2004-07 Impact factor: 4.813
Authors: Miika T Nieminen; Jarno Rieppo; Johanna Silvennoinen; Juha Töyräs; Juhana M Hakumäki; Mika M Hyttinen; Heikki J Helminen; Jukka S Jurvelin Journal: Magn Reson Med Date: 2002-10 Impact factor: 4.668
Authors: Josef Vymazal; Elmar Spuentrup; Gerardo Cardenas-Molina; Andrea J Wiethoff; Michael G Hartmann; Peter Caravan; Edward C Parsons Journal: Invest Radiol Date: 2009-11 Impact factor: 6.016
Authors: L Chaabane; L Tei; L Miragoli; L Lattuada; M von Wronski; F Uggeri; V Lorusso; S Aime Journal: Mol Imaging Biol Date: 2015-12 Impact factor: 3.488
Authors: Patrick M Winter; John Pearce; Zhengtao Chu; Christopher M McPherson; Ray Takigiku; Jing-Huei Lee; Xiaoyang Qi Journal: J Magn Reson Imaging Date: 2014-05-06 Impact factor: 4.813
Authors: Francesco Blasi; Bruno L Oliveira; Tyson A Rietz; Nicholas J Rotile; Helen Day; Richard J Looby; Ilknur Ay; Peter Caravan Journal: J Nucl Med Date: 2014-05-01 Impact factor: 10.057
Authors: Katie L Ciesienski; Yan Yang; Ilknur Ay; Daniel B Chonde; Galen S Loving; Tyson A Rietz; Ciprian Catana; Peter Caravan Journal: Mol Pharm Date: 2013-01-30 Impact factor: 4.939
Authors: Iliyana Atanasova; Mozhdeh Sojoodi; Helena S Leitão; Sergei Shuvaev; Carlos F G C Geraldes; Ricard Masia; Alexander S Guimaraes; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan Journal: Invest Radiol Date: 2020-04 Impact factor: 6.016